NCT03282318View on ClinicalTrials.gov

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

March 21, 2019

Study Completion Date

March 21, 2019

Conditions
Bladder Pain SyndromeInterstitial Cystitis
Interventions
DRUG

ASP6294

Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.

DRUG

Placebo

Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.

Trial Locations (28)

Unknown

Site BE32001, Leuven

Site CZ42002, Pilsen

Site DE49003, Duisburg

Site DE49007, Duisburg

Site DE49001, Holzminden

Site DE49005, Markkleeberg

Site HU36002, Budapest

Site HU36001, Csongrád

Site LV37103, Daugavpils

Site LV37101, Riga

Site LV37102, Riga

Site LV37105, Riga

Site NL31007, Sneek

Site PL48009, Lodz

Site PL48002, Szczecin

Site PL48010, Warsaw

Site PL48007, Wroclaw

Site RU70001, Saint Petersburg

Site RU70002, Saint Petersburg

Site RU70003, Saint Petersburg

Site RU70006, Saint Petersburg

Site RU70008, Saint Petersburg

Site ES34001, Barcelona

Site ES34008, Madrid

Site ES34002, Málaga

Site ES34007, Valencia

Site GB44002, Manchester

Site GB44006, Plymouth

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT03282318 - A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis | Biotech Hunter | Biotech Hunter